Connection | Profiles RNS

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

HONG, DAVID SANGHYUN

One or more keywords matched the following items that are connected to HONG, DAVID SANGHYUN

Item Type	Name
Concept	Pyrimidines
Academic Article	Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.
Academic Article	Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
Academic Article	A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.
Academic Article	Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors.
Academic Article	Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study.
Academic Article	Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.
Academic Article	Targeting TRK family proteins in cancer.
Academic Article	Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
Academic Article	Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Academic Article	Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.
Academic Article	Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma.
Academic Article	A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
Academic Article	A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer.
Academic Article	The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
Academic Article	First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors.
Academic Article	Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.
Academic Article	Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
Academic Article	KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
Academic Article	Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.
Academic Article	Therapeutics Targeting Mutant KRAS.
Academic Article	Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose.
Academic Article	Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib.
Academic Article	NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.
Academic Article	Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors.
Academic Article	Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.
Academic Article	Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib.
Academic Article	Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.
Academic Article	Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial.

Search Criteria

Pyrimidines